Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated April 2, 2024, serves as a notification to the market regarding the company's issued share capital and total voting rights as of March 31, 2024. The report is submitted in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure details:
- Issued Share Capital: 4,314,051,101 Ordinary Shares of 31 1/4 pence each.
- Treasury Shares: 169,171,155 Ordinary Shares held in Treasury.
- Total Voting Rights: 4,114,879,946.
Material Changes
The filing text does not provide comparative data against prior periods to identify material changes in share capital or voting rights.
Guidance, Outlook, and Risks
The document contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It is a statutory notification intended to provide shareholders with the denominator required to calculate notification thresholds under FCA rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,114,879,946) against internal records for compliance with FCA disclosure thresholds.
- Confirm the count of Treasury Shares (169,171,155) to ensure accurate calculation of outstanding shares.
- Check for subsequent filings if share capital changes occur after the March 31, 2024 cutoff.